G Brabant

University Medical Center Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany

Are you G Brabant?

Claim your profile

Publications (254)888.48 Total impact

  • E Kasim · A Omar · S Müller · T Schütz · T Kröncke · H Lochs · G Brabant · J Ockenga
    Zeitschrift für Gastroenterologie 08/2015; 41(08). DOI:10.1055/s-0035-1555535 · 1.05 Impact Factor
  • Experimental and Clinical Endocrinology & Diabetes 03/2015; 122(03). DOI:10.1055/s-0035-1547751 · 1.56 Impact Factor
  • N Zimmermann · G Brabant · N Begum · C Thorns
    Experimental and Clinical Endocrinology & Diabetes 03/2015; 122(03). DOI:10.1055/s-0035-1547628 · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To study the interaction between copeptin and hypothalamic-pituitary-adrenal (HPA) activation in men and women during hypoglycaemic stress.Design and patientsA prospective study in 118 patients (mean age 47.7±13.6 yrs., n=52 women) undergoing insulin tolerance testing for suspected pituitary dysfunction.MeasurementsSerum copeptin was measured in serially collected blood samples and assessed in relation to ACTH, cortisol and other endocrine parameters.ResultsSymptomatic hypoglycaemia (mean glucose nadir, 1.6±0.5 mmol/l) resulted in a rapid significant increase of serum copeptin. Individuals with impaired pituitary function had lower stress-induced copeptin levels (median, 6.26 pmol/l) than patients with intact pituitary (8.46 pmol/l, P < 0.001). A weak overall correlation between stress-induced copeptin and cortisol levels was observed (rs = 0.31, P < 0.001). In female individuals, there was a positive correlation between stress-induced copeptin and ACTH (rs = 0.47, P < 0.001) or cortisol levels (rs = 0.42, P = 0.002), while in males no correlation to ACTH (rs = 0.03, P = 0.75) and poor correlation to cortisol levels (rs = 0.24, P = 0.045). was observed. Patients with central diabetes insipidus showed lowest baseline (2.20 pmol/l) and stimulated copeptin levels (3.68 pmol/l).Conclusions The data from this study indicate that stress-induced release of AVP in women, but not in men, is linked to the co-activation of the hypothalamic-pituitary-adrenal system.This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 09/2014; 82(4). DOI:10.1111/cen.12608 · 3.46 Impact Factor
  • B. Harbeck · A. Marxsen · G. Brabant
    [Show abstract] [Hide abstract]
    ABSTRACT: Funktionsveränderungen der mütterlichen Schilddrüse beeinflussen die frühe fetale Entwicklung. Die Schilddrüsenhormone Trijodthyronin (T3) und Thyroxin (T4) sind für die Entwicklung und das Aufrechterhalten physiologischer Prozesse zwingend erforderlich. Dies gilt insbesondere für das Zentralnervensystem (ZNS); hier sind Schilddrüsenhormone von erheblicher Bedeutung bei der Reifung des fetalen Gehirns während der Schwangerschaft. Neben Schilddrüsenerkrankungen kommt dem Jodmangel erhebliche Bedeutung zu. Während der Schwangerschaft steigt der Bedarf an Schilddrüsenhormonen und entsprechend an Jod um etwa 50 % an. Die gesunde Schilddrüse kann diesen Mehrbedarf decken, sofern eine ausreichende Jodversorgung gewährleistet ist. Der vorliegende Beitrag beschreibt die Vorgänge der fetalen und maternalen Schilddrüsenhormonproduktion und geht im Besonderen auf die physiologischen Veränderungen der mütterlichen Schilddrüsenparameter während der Schwangerschaft ein. Besondere Berücksichtigung finden Schilddrüsenfunktionsstörungen bei Mutter und Fetus. Abstract Functional alterations of maternal thyroid glands influence early fetal development. The thyroid gland hormones triiodothyronine (T3) and thyroxine (T4) are absolutely necessary for the development and maintenance of physiological processes. This is especially true for the central nervous system (CNS) where the thyroid gland hormones play an important role in maturation of the fetal brain during pregnancy. In addition to thyroid gland diseases, iodine deficiency is also extremely important. During pregnancy the requirements for thyroid gland hormones increase by approximately 50 % with a corresponding need for iodine. Healthy thyroid glands can cover these increased requirements as long as sufficient iodine is available. This article describes the processes of fetal and maternal thyroid hormone production and in particular the physiological alterations of maternal thyroid gland parameters during pregnancy. Particular attention is paid to disorders of thyroid gland function in the mother and fetus.
    Gynäkologische Endokrinologie 05/2014; 12(2):96-102. DOI:10.1007/s10304-013-0596-9
  • S Brede · G Brabant · N Begum · H Lehnert · C Thorns
    Experimental and Clinical Endocrinology & Diabetes 03/2014; 122(03). DOI:10.1055/s-0034-1372310 · 1.56 Impact Factor
  • Experimental and Clinical Endocrinology & Diabetes 03/2014; 122(03). DOI:10.1055/s-0034-1372037 · 1.56 Impact Factor
  • H. Biersack · G. Brabant
    [Show abstract] [Hide abstract]
    ABSTRACT: Spätschäden einer Krebserkrankung sind durch die therapiebedingt verbesserten Überlebensraten ein rasch zunehmendes, aber bislang zu wenig wahrgenommenes Problem. Zu diesen Folgeerkrankungen, die definitionsgemäß Jahre nach der initialen Erkrankung auftreten, zählen nicht nur Zweittumoren, sondern auch eine Reihe nichtonkologischer internistischer Probleme. Diese kardiovaskulären, gastrointestinalen, renalen oder endokrinen Spätschäden wurden bislang unzureichend beachtet und müssen bei der häufig schleichenden Symptomatik gezielt adressiert werden.
    Der Internist 12/2013; 54(10). DOI:10.1007/s00108-013-3355-z · 0.31 Impact Factor
  • H Biersack · G Brabant
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to therapy-associated improvements in survival rates, delayed effects of cancer are a rapidly increasing but as yet only poorly recognized problem. These delayed sequelae, which by definition occur years after the primary disease, include secondary tumors and many non-oncological internal medical problems. Little attention has so far been paid to the cardiovascular, gastrointestinal, renal and endocrinal delayed side effects and must be specifically addressed due to the often slowly progressing symptoms.
    Der Internist 09/2013; 19(12). DOI:10.1007/s00761-013-2632-8 · 0.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Headache is very common in pituitary disease and is reported to be present in more than a third of all patients with pituitary adenomas. Tumour size, cavernous sinus invasion, traction or displacement of intracranial pain-sensitive structures such as blood vessels, cranial nerves and dura mater, and hormonal hypersecretion are implicated causes. The present review attempts to systematically review the literature for any combination of headache and pituitary or hormone overproduction or deficiency. Most data available are retrospective and/or not based on the International Headache Society (IHS) classification. Whereas in pituitary apoplexy a mechanical component explains the almost universal association of the condition with headaches, this correlation is less clear in other forms of pituitary disease and a positive impact of surgery on headaches is not guaranteed. Similarly, invasion into the cavernous sinus or local inflammatory changes have been linked to headaches without convincing evidence. Some studies suggest that oversecretion of GH and prolactin may be important for the development of headaches and treatment, particularly with somatostatin analogues, has been shown to improve symptoms in these patients. Otherwise, treatment rests on general treatment options for headaches based an accurate clinical history and a precise classification which includes assessment of the patient's psychosocial risk factors. This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 08/2013; 79(6). DOI:10.1111/cen.12314 · 3.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Direct measurement of arginine-vasopressin/antidiuretic hormone (AVP/ADH) concentrations is not included in the standard diagnostic procedures for paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Here, we evaluate the potential of copeptin measurement as a surrogate marker of AVP/ADH secretion for the direct diagnosis of suspected SIADH in cancer patients. Forty-six unselected cancer patients with serum sodium concentrations permanently below 135 mmol/L were included in this study. We compared standard diagnostic criteria for SIADH to the measurement of plasma copeptin in relation to osmolality. Normative data for comparison were constructed from 24 healthy controls studied under basal conditions, experimental dehydration, and hypotonic hypervolemia as well as from 222 hospital patients with no suspicion of an altered ADH regulation. Log transformation of copeptin revealed a linear relationship to plasma osmolality in the controls (R = 0.495, p < 0.001). Compared to these normative data, copeptin levels in most cancer patients were inappropriately high for plasma osmolality and were not significantly correlated. These results, suggestive for paraneoplastic SIADH, could be confirmed by conventional diagnostic procedures for SIADH. Current strategies to diagnose SIADH are difficult to perform under outpatients conditions. Our approach allows screening from a single plasma sample for true paraneoplastic ADH oversecretion and thus rapid selection for a specific therapy with an AVP receptor antagonist.
    Endocrine 03/2013; 44(3). DOI:10.1007/s12020-013-9919-9 · 3.88 Impact Factor
  • Experimental and Clinical Endocrinology & Diabetes 03/2013; 121(03). DOI:10.1055/s-0033-1336644 · 1.56 Impact Factor
  • Experimental and Clinical Endocrinology & Diabetes 03/2013; 121(03). DOI:10.1055/s-0033-1336656 · 1.56 Impact Factor
  • KA Iwen · O Hiort · S Biskup · Y Hellenbroich · G Brabant
    Experimental and Clinical Endocrinology & Diabetes 03/2013; 121(03). DOI:10.1055/s-0033-1336626 · 1.56 Impact Factor
  • Experimental and Clinical Endocrinology & Diabetes 03/2013; 121(03). DOI:10.1055/s-0033-1336687 · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to examine potential implications of changes in the approach to adult growth hormone (GH) replacement (GHR) over the last 15 years. Therefore, we analysed the German KIMS database as one of the largest single country pharmacoepidemiological databases on adult GH deficiency (GHD). Based on the date of their first GH application patients were assigned to three intervals (1995-1999, 2000-2004, 2005-2009). A multivariate analysis of variance with interval and sex as independent variables was conducted. Differences were analysed with respect to IGF-I standard deviation score (SDS), quality of life, latency between GHD diagnosis and first GH dose, body mass index, waist-hip ratio, lipid profile, and GH dose. All analyses were conducted at baseline, 1 year, and 3 years of GHR. We detected significant associations between time interval and patient characteristics at baseline and with treatment effects. Recently, patients with less severe GHD (mean IGF-I SDS: -2.1, -1.6, -1.0 in the 1st, 2nd and 3rd interval; p = 0.000) are treated with lower GH starting doses (mean 0.30, 0.19, 0.21 mg/day in the 1st, 2nd and 3rd interval; p = 0.000). In the first time interval, IGF-I SDS was not normalized in females after 3 years of GHR. The results of our analysis demonstrate prominent changes in patient characteristics and handling of GHR. They highlight that approach to therapy and patient inclusion criteria change over time and may represent an important confounder for any analysis in epidemiological surveillance surveys.
    Pituitary 07/2012; 15 Suppl 1(1). DOI:10.1007/s11102-012-0410-z · 3.20 Impact Factor
  • C Hubold · G Brabant
    [Show abstract] [Hide abstract]
    ABSTRACT: Ectopic hormone production is a rare complication in neuroendocrine tumors. Tumors producing corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) are most commonly observed, leading to the classical symptoms of Cushing’s syndrome. Additionally, a very low percentage of neuroendocrine tumors can produce growth hormone-releasing hormone (GHRH) leading to classical features of acromegaly. Moreover, ectopic antidiuretic hormone (ADH) secretion has been described in neuroendocrine tumors presenting as hyponatremia due to the syndrome of inappropriate ADH secretion. Other ectopic hormone secretions, such as paraneoplastic gonadotropin release are rarely observed. Ectopic hormone secretion is not usually associated with a detectable pituitary mass and diagnosis is based on the measurement of circulating peptides. This is frequently assisted by imaging techniques, such as somatostatin receptor scintigraphy. Therapeutically a curative approach is the primary goal but in advanced tumors palliative treatment aims to control symptoms with the help of specific antihormonal compounds, such as somatostatin analogues.
    Der Internist 02/2012; 53(2):145-51. DOI:10.1007/s00108-011-2920-6 · 0.31 Impact Factor
  • Dr. B. Harbeck · G. Brabant
    [Show abstract] [Hide abstract]
    ABSTRACT: Schilddrüsenfunktionsstörungen beeinflussen die Fertilität von Frauen wie auch von Männern. Wesentliche Pathomechanismen sind die durch eine Hypothyreose bedingte Hyperprolaktinämie sowie eine Änderung der Plasmabindungsaktivität des sexualhormonbindenden Globulins (SHBG). Bei Männern können klinisch insbesondere Erektionsstörungen und eine Verminderung der Spermienqualität auftreten, während bei Frauen Zyklusstörungen (Amenorrhö, Oligomenorrhö) im Vordergrund stehen. Es gibt deutliche Hinweise, dass schon eine subklinische Hypothyreose zu einer Störung der Fertilität führen kann, weshalb bei Vorliegen einer Infertilität die Schilddrüsenfunktion überprüft werden sollte. Obwohl die aktuelle Datenlage noch keine abschließenden Aussagen zulässt, erscheint die Substitutionstherapie mit dem Ziel eines optimalen Thyreotropin(TSH)-Spiegels von 1–2 mIE/l sinnvoll, da auf diese Weise in einzelnen Studien die Chance auf Fertilität und erfolgreiche Schwangerschaften erhöht wurde. Die Hyperthyreose führt über eine Stimulation von SHBG bei beiden Geschlechtern zu erhöhten Gesamttestosteron- und Östradiolspiegeln. Klinisch stehen bei der Frau auch hier Zyklusstörungen im Vordergrund. Auch wenn die Studienlage insgesamt unzureichend ist, gibt es bei Männern Hinweise auf eine erhöhte Prävalenz von Erektionsstörungen sowie eine verminderte Spermienzahl und -motilität. Die Prävalenz einer subklinischen oder manifesten Hyperthyreose beträgt bei infertilen Frauen 2,1% und ist somit vergleichbar zur Häufigkeit in einer fertilen Population.
    Gynäkologische Endokrinologie 02/2012; 10(1). DOI:10.1007/s10304-011-0446-6
  • Endocrine Practice 01/2012; 18(3):325-34. · 2.81 Impact Factor
  • Source
    S Kenz · C S Haas · S C Werth · S Bohnet · G Brabant
    Annals of Oncology 12/2011; 22(12):2696. DOI:10.1093/annonc/mdr431 · 7.04 Impact Factor

Publication Stats

4k Citations
888.48 Total Impact Points


  • 2013
    • University Medical Center Schleswig-Holstein
      Kiel, Schleswig-Holstein, Germany
  • 2012–2013
    • Universitätsklinikum Schleswig - Holstein
      Kiel, Schleswig-Holstein, Germany
    • Universität zu Lübeck
      Lübeck Hansestadt, Schleswig-Holstein, Germany
  • 2008–2011
    • The University of Manchester
      • School of Pharmacy and Pharmaceutical Sciences
      Manchester, England, United Kingdom
  • 2010
    • Friedrich-Alexander-University of Erlangen-Nürnberg
      Erlangen, Bavaria, Germany
  • 1984–2010
    • Hannover Medical School
      • • Department of Gastroenterology, Hepatology and Endocrinology
      • • Department of Nuclear Medicine
      Hannover, Lower Saxony, Germany
  • 2004
    • University of Udine
      Udine, Friuli Venezia Giulia, Italy
    • Technische Universität Dresden
      Dresden, Saxony, Germany
  • 2001–2003
    • Hochschule Hannover
      Hanover, Lower Saxony, Germany
  • 1998
    • Universität Regensburg
      Ratisbon, Bavaria, Germany
    • Academy of Sciences of the Czech Republic
      • Ústav informatiky
      Praha, Hlavni mesto Praha, Czech Republic
  • 1996
    • Martin Luther University of Halle-Wittenberg
      Halle-on-the-Saale, Saxony-Anhalt, Germany
  • 1995
    • Vrije Universiteit Brussel
      Bruxelles, Brussels Capital, Belgium
    • Salk Institute
      La Jolla, California, United States
  • 1993–1994
    • University of Amsterdam
      • Department of Endocrinology
      Amsterdamo, North Holland, Netherlands